DRAK1 can interrupt the formation of the Smad3/Smad4 complex by binding to Smad3, a process that inhibits TGF-β tumor suppressor signaling in head and neck squamous cell carcinoma (HNSCC) and increases tumor activity (Park et al., 2015). Here, SMAD4 is linked to head and neck squamous cell carcinoma.